Bio

Gossamer Bio Announces Third Quarter 2023 Financial Results and Provides Business Update

Retrieved on: 
Thursday, November 9, 2023
Biotechnology, Health, Pharmaceutical, Clinical Trials, Cardiology, Research, Research and development, Stanford University, Bio, III, Public expenditure, G&A, Functional, Orthostatic hypertension, Entrepreneurship, R, Gossamer, Critical Care Medicine (journal), GOSS, FRI, Security (finance), PAH, Site, Patient, Administration, Pharmaceutical industry

Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH), today announced its financial results for the third quarter ended September 30, 2023, and provided a business update.

Key Points: 
  • Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH), today announced its financial results for the third quarter ended September 30, 2023, and provided a business update.
  • “Additionally, we were excited to have presented the results from the Phase 2 TORREY lung imaging sub-study presented at the European Respiratory Society International Congress 2023.
  • Gossamer expects to release further TORREY OLE data from the ongoing extension study in PAH patients in the fourth quarter of 2023.
  • Financial Results for Quarter Ended September 30, 2023
    Cash, Cash Equivalents and Marketable Securities: Cash, cash equivalents and marketable securities as of September 30, 2023, were $328.9 million.

Adicet Reports Third Quarter 2023 Financial Results and Provides Business Updates

Retrieved on: 
Wednesday, November 8, 2023
Science, Stem Cells, Biotechnology, Research, Pharmaceutical, Oncology, Health, Clinical Trials, CAR, Trial of the century, IND, Food, Bio, CD70, Renal cell carcinoma, International Conference on Afghanistan, London (2010), CD20, Society for Immunotherapy of Cancer, Tropism, TGF, Conference, CDMO, Regulation of tobacco by the U.S. Food and Drug Administration, Prostate cancer, R, Engineering, Poster, Goodwill, SITC, Immunotherapy, MCL, Research and development, Annual general meeting, Probability, ACET, Tumor microenvironment, Epitope, NHL, Society, Cancer, PSMA, Patient, Administration, Prognosis, Prostate, CD27, Pharmaceutical industry, Cryptocurrency

Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today reported financial results and operational highlights for the third quarter ended September 30, 2023.

Key Points: 
  • Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today reported financial results and operational highlights for the third quarter ended September 30, 2023.
  • In October 2023, Adicet presented new preclinical data building on the potential of Adicet’s allogeneic gamma delta platform as a promising approach to target prostate cancer.
  • Financial Results for Third Quarter 2023:
    Research and Development (R&D) Expenses: R&D expenses were $26.2 million for the three months ended September 30, 2023, compared to $16.6 million during the same period in 2022.
  • Cash Position: Cash and cash equivalents were $183.3 million as of September 30, 2023, compared to $257.7 million as of December 31, 2022.

Assembly Biosciences Names Anuj Gaggar, MD, PhD, as Chief Medical Officer

Retrieved on: 
Wednesday, November 8, 2023
University of Washington Department of Global Health, Stanford University, Bio, Infection, Therapy, Viral, Biotechnology, Herpes simplex virus, BS, MD, Publication, Doctor of Philosophy, Gilead Sciences, Sofosbuvir, University, Assembly, HCV, Virology, Chemistry, Patient, HDV, HBV, SAN, Pharmaceutical industry

SOUTH SAN FRANCISCO, Calif., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative antiviral therapeutics targeting serious viral diseases, today announced that Anuj Gaggar, MD, PhD, has joined the company as chief medical officer. Dr. Gaggar is an infectious disease specialist and seasoned executive whose experience has focused on the development of new therapies in viral diseases including chronic hepatitis B virus (HBV), hepatitis C virus (HCV) and hepatitis D virus (HDV) infections.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative antiviral therapeutics targeting serious viral diseases, today announced that Anuj Gaggar, MD, PhD, has joined the company as chief medical officer.
  • “We are excited to have Dr. Gaggar join Assembly Bio’s leadership team at an incredibly important time for the organization,” said Jason Okazaki, chief executive officer and president.
  • Dr. Gaggar was a clinical fellow in infectious diseases at the University of California, San Francisco, where he also served as chief resident.
  • He received his MD and PhD from the University of Washington and his BS in chemistry from Stanford University.

Adicet Bio to Present at the 2023 Jefferies London Healthcare Conference

Retrieved on: 
Tuesday, November 7, 2023
Science, Stem Cells, Biotechnology, Research, Pharmaceutical, Oncology, Health, Clinical Trials, ACET, Cancer, Conference, Bio, Pharmaceutical industry

Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today announced that Chen Schor, President and Chief Executive Officer, will present at the 2023 Jefferies London Healthcare Conference being held from November 14-16, 2023 in London.

Key Points: 
  • Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today announced that Chen Schor, President and Chief Executive Officer, will present at the 2023 Jefferies London Healthcare Conference being held from November 14-16, 2023 in London.
  • Details of the event are as follows:
    The live audio webcast of the presentation can be accessed on the Investors section of Adicet Bio’s website at http://www.adicetbio.com .
  • An archived replay will be available for 30 days following the presentation.

Adicet Bio Announces Poster Presentation Highlighting ADI-001 Data at the 65th American Society of Hematology (ASH) Annual Meeting

Retrieved on: 
Thursday, November 2, 2023
Oncology, Health, Clinical Trials, Research, Science, Biotechnology, ASH, Pharmacodynamics, ACET, Patient, Cancer, PDT, Bio, American Society for Investigative Pathology, Society, Pharmaceutical industry

Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today announced the acceptance of a poster presentation at the upcoming 65th American Society of Hematology (ASH) Annual Meeting to be held in San Diego, CA from December 9-12, 2023.

Key Points: 
  • Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today announced the acceptance of a poster presentation at the upcoming 65th American Society of Hematology (ASH) Annual Meeting to be held in San Diego, CA from December 9-12, 2023.
  • Details of the poster presentation are as follows:
    Title: Expansion, Persistence and Pharmacodynamic Profile of ADI-001, a First-in-Class Allogeneic CD20-Targeted CAR Gamma Delta T Cell Therapy, in Patients with Relapsed/Refractory Aggressive B-Cell Non-Hodgkin’s Lymphoma
    Session Name: 704.
  • Cellular Immunotherapies: Early Phase and Investigational Therapies: Poster II
    Date/Time: Sunday, December 10, 2023, from 6:00 - 8:00 p.m. PDT

Orca Bio to Present Positive Clinical Data on its Novel High-Precision Cell Therapies at the 65th American Society of Hematology Annual Meeting

Retrieved on: 
Thursday, November 2, 2023
Biotechnology, Health, Science, Research, Oncology, Bio, Lymphoma, Safety, Society, ASH, Bone marrow, Abstract, Cancer, American Society for Investigative Pathology, Pharmaceutical industry, Patient, Leukemia

Orca Bio, a late-stage biotechnology company developing high-precision cell therapies for the treatment of cancer, autoimmune diseases and genetic blood disorders, today announced that new data will be presented at the American Society of Hematology (ASH) Annual Meeting from December 9-12 in San Diego, CA.

Key Points: 
  • Orca Bio, a late-stage biotechnology company developing high-precision cell therapies for the treatment of cancer, autoimmune diseases and genetic blood disorders, today announced that new data will be presented at the American Society of Hematology (ASH) Annual Meeting from December 9-12 in San Diego, CA.
  • Specifically, an oral presentation will highlight the outcomes of myeloablative Orca-T, Orca Bio’s lead investigational high-precision cell therapy, in patients over the age of 55.
  • A second oral presentation will share updated results in an expanded group of patients with haploidentical donors treated with Orca Bio’s second investigational high-precision cell therapy, Orca-Q.
  • Cellular Immunotherapies: Early Phase and Investigational Therapies: Novel Approaches to Enhance Cellular Therapies and Immune Responses in Leukemias and Lymphomas

Pivot Bio Appoints Industry Veteran to Lead Manufacturing & Supply Chain

Retrieved on: 
Wednesday, November 1, 2023
Sustainability, Agriculture, Natural Resources, Environment, Corn Belt, Bio, DuPont, Food, Global Operations, Kansas Department of Agriculture, Division of Water Resources, Venkataraman, San Francisco Bay Area, Farmer, Dow Chemical Company, Safety, University City (Charlotte neighborhood), OS, Fine chemical

Pivot Bio, Inc ., a sustainable agriculture company delivering farmers patented crop nutrition technologies that harness the power of nature to reliably and productively grow the food the world needs, has named Balaji Venkataraman Senior Vice President of Manufacturing and Supply Chain to lead in-house and third-party manufacturing, supply chain and procurement.

Key Points: 
  • Pivot Bio, Inc ., a sustainable agriculture company delivering farmers patented crop nutrition technologies that harness the power of nature to reliably and productively grow the food the world needs, has named Balaji Venkataraman Senior Vice President of Manufacturing and Supply Chain to lead in-house and third-party manufacturing, supply chain and procurement.
  • “Balaji brings decades of expertise as a global operations leader – transforming supply chains, working with teams to deliver operational excellence, and optimizing processes to improve safety and profitability,” said Safarian.
  • Venkataraman comes to Pivot Bio from Corteva Agriscience where he was Vice President of Global Operations.
  • Prior to that, he held a variety of manufacturing leadership roles across Dow companies including the Agriculture Division of DowDuPont and Dow Chemical in the U.S. and India.

Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Tuesday, October 31, 2023
Biotechnology, Health, Genetics, Clinical Trials, Oncology, ACET, Cancer, Employment, Bio, Pharmaceutical industry

Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today announced it granted an inducement award on October 31, 2023.

Key Points: 
  • Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today announced it granted an inducement award on October 31, 2023.
  • One individual was hired by Adicet in October 2023 and granted new hire non-qualified stock options to purchase 5,000 shares of Adicet’s common stock with an exercise price of $1.32 per share, the closing price of Adicet’s common stock as reported by Nasdaq on October 31, 2023.
  • The above-described award was granted outside of Adicet’s stockholder-approved equity incentive plans pursuant to Adicet’s 2022 Inducement Plan (the Inducement Plan), which was adopted by the board of directors in January 2022 and subsequently amended in January 2023.
  • The award was authorized by the compensation committee of the board of directors, which is comprised solely of independent directors, as a material inducement to the employee entering into employment with Adicet in accordance with Nasdaq Listing Rule 5635(c)(4).

Annovis Bio Announces Pricing of $7.5 Million Public Offering

Retrieved on: 
Tuesday, October 31, 2023
Biotechnology, Health, General Health, Pharmaceutical, Neurology, Mental Health, Health Technology, Other Science, Research, Science, Clinical Trials, Suite, Sale, Security (finance), NYSE, Bio, Canaccord Genuity, Form, Attention, High Street, Prospectus

The combined offering price to the public of each share of common stock and accompanying warrant is $6.00.

Key Points: 
  • The combined offering price to the public of each share of common stock and accompanying warrant is $6.00.
  • All of the shares of common stock and the accompanying warrant are being offered by Annovis.
  • The shares of common stock and the accompanying warrant will be issued separately but can only be purchased together in the offering.
  • Before deducting the underwriting discounts and commissions and other offering expenses, Annovis expects to receive total gross proceeds of approximately $7.5 million.

IUPAC Selects Glycan Trimming Technology used in Uvax Bio’s HIV-1 Vaccine Design and Manufacturing as one of the Top Ten Emerging Technologies in Chemistry for 2023

Retrieved on: 
Wednesday, November 1, 2023
AIDS, Health, Infectious Diseases, Research, Science, Pharmaceutical, Biotechnology, Rat, Hook effect, Bio, International Union of Pure and Applied Chemistry, Scripps Research, Computational biology, Face, HIV, Mouse, Immune system, IUPAC, ID50, GMP, Patient, Associate, Vaccine, Chemistry

The IUPAC described this technology as “low-sugar vaccinations.”

Key Points: 
  • The IUPAC described this technology as “low-sugar vaccinations.”
    Glycans are long, branched sugar molecules that are commonly attached to viral surface proteins.
  • But the glycan coating can also contribute to the immune response.
  • Finally, Zhu decided to remove most (but not all) of the glycan shield through an enzymatic process.
  • “We congratulate Prof. Zhu and his team at Scripps Research on this recognition of their innovative work in HIV vaccine design and chemistry.